Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer ... The 7-year invasive disease–free survival in the IHC 3+ cohorts (total, 1132 patients) was ...

HER2 classification relies on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), which examines the number of copies of the HER2 gene inside a cancer cell. "On FISH ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

The analysis was performed on independent study sets of HER2-positive and negative/low breast cancers, already analyzed by central immunohistochemistry (IHC) and FISH testing. Phospho-HER2 and ...